April 19, 2006
AMERIPATH, INC. ACQUISITION OF ROSE PATHOLOGY ASSOCIATES, DENVER, COLORADO

FOR IMMEDIATE RELEASE

Contact: David L. Redmond, President and Chief Financial Officer
Phone: 561.712.6226
E-Mail: dredmond@ameripath.com

PALM BEACH GARDENS, FLORIDA, April 19, 2006 — AmeriPath, Inc. (“AmeriPath”), a leading national provider of anatomic pathology, dermatopathology and molecular diagnostics services, today announced the acquisition of Rose Pathology Associates, P.C. The acquisition represents AmeriPath’s latest effort to expand its Colorado-based services.

Stephen W. Aldred, M.D., AmeriPath’s West Regional President commented, “We are excited that Rose Pathology Associates is joining our group in the Denver market. We will be able to expand our geographic coverage as well as continue our strategy of providing localized, specialized, and integrated pathology services. With our esoteric testing capabilities through Specialty Laboratories, Inc., and our national network of leading pathologists, we will be able to better support community-based medicine for enhanced patient care.”

The AmeriPath-Rose Pathology Associates partnership will enhance pathology services to both hospital and outpatient practices in the region. Rose Pathology Associates is well-established at two progressive medical complexes in the Denver area, which provide for certain opportunities for rapid market growth. Rose Pathology Associates’ team of pathology specialists complements and reinforces the expertise of the current AmeriPath Denver team. Rose Pathology Associates’ specialists, qualified in pulmonary pathology, cytopathology, and hematopathology, also include a fellowship-trained breast pathologist.

“We are excited about partnering with AmeriPath. They are very customer oriented and they have the resources to help us better serve our referring doctors” added Dr. Greg Achenbach of Rose Pathology Associates.

AmeriPath Colorado (Colorado Pathology Consultants) is a dedicated group of 20 pathologists and over 100 employees providing specialized anatomic and clinical pathology services to clients throughout the state of Colorado.

Michael Pushchak, M.D., Managing Director of AmeriPath Colorado, stated, “I am thrilled to welcome Rose Pathology Associates to AmeriPath. They are a long-standing and highly respected pathology practice in the Denver area. This transaction will clearly strengthen our ability to provide state of the art sub-specialized pathology services to the patients, doctors, and hospital systems that we serve.”

About AmeriPath, Inc.
AmeriPath, a leading national provider of physician-based anatomic pathology, dermatopathology and molecular diagnostic services to physicians, hospitals, clinical laboratories and surgery centers, supports community-based medicine by helping physicians provide excellent and effective care for their patients. A team of subspecialized pathologists and Ph.D. scientists provide medical expertise, diagnostic quality, and personal consultation services. AmeriPath’s team of more than 400 highly trained, board-certified pathologists and Ph.D.-level scientists provide medical diagnostics services in outpatient laboratories owned, operated and managed by AmeriPath, as well as in hospitals and ambulatory surgical centers.

About Specialty Laboratories, Inc.
Specialty Laboratories supports local pathology and community-based medicine by partnering with pathologists and hospitals to improve patient care and reduce episodesof- care costs. Specialty offers hospitals an extensive menu of highly advanced clinical tests used by physicians to diagnose, monitor, and treat disease and a single-source solution for esoteric testing needs. Specialty’s Web address is http://www.specialtylabs.com.

..........................................................

The above statements include forward-looking statements based on current management expectations. Such statements are sometimes identified by words such as “may,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “project” and similar expressions and may include financial or operating estimates, forecasts or projections. Numerous factors exist which may cause results to differ materially from these expectations. Many of the factors that will determine the Company’s future results are beyond the ability of the Company to control or predict and these forward-looking statements are subject to risks and uncertainties relating to the Company, including without limitation (i) possible changes in reimbursement rates under government and third party healthcare programs and the payments received under such programs, (ii) the Company’s ability to attract, motivate and retain pathologists and senior management, (iii) risks associated with the Company’s acquisition strategies, including without limitation the successful completion and integration of acquisitions (and achievement of planned or expected synergies) and the availability of pathology practices in appropriate locations that the Company is able to acquire on suitable terms or develop, (iv) federal and state healthcare regulation (and compliance), (v) changes in coding, (vi) the highly competitive nature of the healthcare business, and (vii) those risks and uncertainties detailed from time to time in the Company’s filings with the SEC. Therefore, the Company’s actual results may differ materially. The Company undertakes no obligation to update any forward-looking statements or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.